Antisense-based cancer therapeutics: are we there yet? (Q36458427)

14 August 2017

1 reference

title

Antisense-based cancer therapeutics: are we there yet? (English)

1 reference

14 August 2017

3

Ruiwen Zhang

1 reference

14 August 2017

2

Hui Wang

1 reference

14 August 2017

Elizabeth Rose Rayburn

series ordinal

1

1 reference

PubMed ID

16634705

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Expert Opinion on Emerging Drugs

14 August 2017

1 reference

14 August 2017

11

1 reference

14 August 2017

2

1 reference

14 August 2017

337-352

1 reference

Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Therapeutics targeting signal transduction for patients with colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Antisense approaches in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Second neoplasms after megavoltage radiation for pediatric tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Antisense therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Use of antisense oligonucleotides in functional genomics and target validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Survivin, versatile modulation of cell division and apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

DNA-based therapeutics and DNA delivery systems: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Technical improvements in the computational target search for antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

The future of antisense therapy: combination with anticancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Aptamers: an emerging class of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Role of RNase H in hybrid-arrested translation by antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Molecular mechanisms of action of antisense drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Antisense technologies. Improvement through novel chemical modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Structural modifications of antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Antisense oligonucleotide-based therapeutics for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

TGF-beta inhibitors for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Chemosensitization by antisense oligonucleotides targeting MDM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Survivin as a target for new anticancer interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

The role of protein kinase C-alpha (PKC-alpha) in malignancies of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

The prospect of silencing disease using RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Innovations in oligonucleotide drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Delivery systems for antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

NLS bioconjugates for targeting therapeutic genes to the nucleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Increased uptake of antisense oligonucleotides by delivery as double stranded complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Poly-L-lysine-modified silica nanoparticles: a potential oral gene delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Engineering synthetic vectors for improved DNA delivery: insights from intracellular pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Cationic compounds used in lipoplexes and polyplexes for gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Toxicology of antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

CpG motifs in bacterial DNA and their immune effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Ribozyme-mediated revision of RNA and DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Functional repair of a mutant chloride channel using a trans-splicing ribozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Synthetic hammerhead ribozymes as therapeutic tools to control disease genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Assembly and function of RNA silencing complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

RNA-interference-based functional genomics in mammalian cells: reverse genetics coming of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Albumin–protamine–oligonucleotide nanoparticles as a new antisense delivery system. Part 1: Physicochemical characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Antisense approaches in drug discovery and development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Vitravene--another piece in the mosaic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Ten years of antisense inhibition of brain G-protein-coupled receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.337

10.1517/14728214.11.2.337

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16634705